id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2022-D-0084-0021,FDA,FDA-2022-D-0084,Use of Circulating Tumor Deoxyribonucleic Acid for Curative- Intent Solid Tumor Drug Development; Guidance for Industry; Availability,Notice,Notice of Availability,2024-11-29T05:00:00Z,2024,11,2024-11-29T05:00:00Z,,2024-11-29T15:07:39Z,2024-28033,0,0,090000648683f00a
FDA-2022-D-0084-0022,FDA,FDA-2022-D-0084,Use of Circulating Tumor DNA for Curative-Intent Solid Tumor Drug Development; Guidance for Industry,Other,Guidance,2024-11-29T05:00:00Z,2024,11,2024-11-29T05:00:00Z,,2024-11-29T15:14:35Z,,1,0,090000648683ebf0
FDA-2022-D-0084-0001,FDA,FDA-2022-D-0084,Use of Circulating Tumor Deoxyribonucleic Acid for Early-Stage Solid Tumor Drug Development; Draft Guidance for Industry; Availability,Notice,Notice of Availability,2022-05-03T04:00:00Z,2022,5,2022-05-03T04:00:00Z,,2022-07-06T01:00:44Z,2022-09459,0,0,0900006485049959
FDA-2022-D-0084-0002,FDA,FDA-2022-D-0084,Use of Circulating Tumor DNA for Early-Stage Solid Tumor Drug Development Guidance for Industry,Other,Guidance,2022-05-03T04:00:00Z,2022,5,2022-05-03T04:00:00Z,2022-07-06T03:59:59Z,2024-11-29T15:13:59Z,,0,0,090000648504a1db